Rifampin chemoprophylaxis for household contacts of patients with invasive infections due to Haemophilus influenzae type b.
To determine the efficacy of rifampin chemoprophylaxis in eradication of oropharyngeal carriage of Haemophilus influenzae type b, we conducted a multicenter, double-blind, placebo-controlled trial among household contacts of patients hospitalized for invasive HIB infection. Seventy-nine index patients and 400 close contacts were studied; 26.5% of contacts were colonized. The efficacy of rifampin (10 mg/kg/dose, 600 mg/dose maximum, twice daily for two days) in eradicating carriage was 52% and varied with age (75.6% in persons greater than or equal to 5 and 27% in those less than 5 years). Eradication rates in those less than 5 years were not significantly better than for placebo. No resistant isolates were encountered in sensitivity testing. The low efficacy of this rifampin regimen in young children precludes its routine use as a chemoprophylactic agent for family contacts. The occurrence of three cases of invasive HIB infection in individuals outside the defined contact group raises concern regarding the efficacy of any chemoprophylactic regimen.
D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004825:Epiglottis / Q000382:microbiology; D005260:Female; D006192:Haemophilus Infections / Q000517:prevention & control* / Q000635:transmission; D006193:Haemophilus influenzae; D006801:Humans; D007223:Infant; D007827:Laryngitis / Q000517:prevention & control / Q000635:transmission; D008583:Meningitis, Haemophilus / Q000517:prevention & control / Q000635:transmission; D008826:Microbial Sensitivity Tests; D009960:Oropharynx / Q000382:microbiology; D010919:Placebos; D011247:Pregnancy; D012293:Rifampin / Q000009:adverse effects / Q000627:therapeutic use*
D010919:Placebos; D012293:Rifampin